体外生命支持中降低抗凝目标(RATE):一项随机对照试验的研究方案
RATE是一项三臂非劣效性随机对照试验,纳入接受体外膜肺氧合(ECMO)治疗的成人患者,比较普通肝素使活化部分凝血活酶时间(aPTT)达基线2-2.5倍、1.5-2倍,以及按体重和肾功能给予低分子肝素三种抗凝策略。主要终点为6个月内大出血(含出血性卒中)、严重血栓栓塞并发症(含缺血性卒中)和死亡的复合终点。作者假设降低抗凝目标或使用低分子肝素可减少出血并发症而不增加血栓栓塞并发症或对结局产生负面影响。
要点
- ECMO治疗死亡率高,缺血性卒中发生率为1.2%,出血并发症发生率为55%。
- aPTT与罕见缺血性卒中无关系,但与更常见的出血并发症和输血有关系。
- 研究比较三种抗凝策略,主要终点为6个月大出血、严重血栓栓塞和死亡的复合终点。
核心结论
- 作者假设在ECMO治疗期间采用较低抗凝目标或低分子肝素抗凝,患者出血并发症会更少,而不增加血栓栓塞并发症或对结局产生负面影响。
- 若假设得到证实,本研究可能导致抗凝方案改变并改善ECMO治疗患者的结局。
研究设计与样本
- 三臂非劣效性随机对照试验,纳入接受ECMO治疗的成人患者。
- 参与者随机分配至普通肝素使aPTT达基线2-2.5倍、普通肝素使aPTT达基线1.5-2倍、或按体重和肾功能给予低分子肝素三组。
- 除抗凝目标外,治疗按标准诊疗进行。
- 主要终点为6个月内大出血(包括出血性卒中)、严重血栓栓塞并发症(包括缺血性卒中)和死亡的复合终点。
- 试验注册于ClinicalTrials.gov NCT04536272(2020年9月2日注册)和荷兰试验注册库NL7969。
主要发现
- aPTT与罕见缺血性卒中的发生(1.2%)无关系,但与更频繁发生的出血并发症(55%)和输血有关系。
- 出血并发症和输血均与结局强相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although life-saving in selected patients, ECMO treatment still has high mortality which for a large part is due to treatment-related complications. A feared complication is ischemic stroke for which heparin is routinely administered for which the dosage is usually guided by activated partial thromboplastin time (aPTT). However, there is no relation between aPTT and the rare occurrence of ischemic stroke (1.2%), but there is a relation with the much more frequent occurrence of bleeding complications (55%) and blood transfusion. Both are strongly related to outcome. METHODS: We will conduct a three-arm non-inferiority randomized controlled trial, in adult patients treated with ECMO. Participants will be randomized between heparin administration with a target of 2-2.5 times baseline aPTT, 1.5-2 times baseline aPTT, or low molecular weight heparin guided by weight and renal function. Apart from anticoagulation targets, treatment will be according to standard care. The primary outcome parameter is a combined endpoint consisting of major bleeding including hemorrhagic stroke, severe thromboembolic complications including ischemic stroke, and mortality at 6 months. DISCUSSION: We hypothesize that with lower anticoagulation targets or anticoagulation with LMWH during ECMO therapy, patients will have fewer hemorrhagic complications without an increase in thromboembolic complication or a negative effect on their outcome. If our hypothesis is confirmed, this study could lead to a change in anticoagulation protocols and a better outcome for patients treated with ECMO. TRIAL REGISTRATION: ClinicalTrials.gov NCT04536272 . Registered on 2 September 2020. Netherlands Trial Register NL7969.
引用
- van Minnen O, Oude Lansink-Hartgring A, van den Boogaard B, et al. Reduced anticoagulation targets in extracorporeal life support (RATE): study protocol for a randomized controlled trial. Trials. 2022. PMID: 35578271. doi:10.1186/s13063-022-06367-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。